News

  1. Leading Clinical And Data Management Talent Will Fuel DaVita Clinical Research's New Denver Facility 6/26/2012

    DaVita Clinical Research (DCR), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, has hired four individuals to ignite the expansion of DCR at its latest clinical research facility in Denver, Colo., scheduled to open this month. 

  2. Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial 5/16/2012

    Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.

  3. Mucosis Announces Positive Proof-Of-Concept Data For Mimopath® Platform In Humans 5/10/2012

    Dutch vaccine development company Mucosis B.V. today announced Phase I clinical data providing proof-of-concept that Mimopath®-based mucosal vaccines are safe and well tolerated as well as able to produce balanced immune responses in both circulating blood and the respiratory tract.

  4. Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA 5/8/2012

    Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, recently announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

  5. Clinical Trial Highlights Positive Oncoprex Results In Lung Cancer Patients 4/27/2012

    A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients.

  6. Merck Presents Results Of A Phase I Clinical Trial Evaluating Investigational BACE Inhibitor MK-8931 At American Academy Of Neurology 4/27/2012

    Merck, known as MSD outside the United States and Canada, recently presented Phase I data evaluating the safety and tolerability of its novel, oral β-amyloid precursor protein site cleaving enzyme (BACE) inhibitor, MK-8931, being investigated as a potential treatment for Alzheimer's disease.

  7. AMRI Signs Exclusive Option To License Its Tubulin Inhibitor Program For Cancer 4/9/2012
    AMRI, a global contract healthcare services organization spanning the entire R&D continuum, announced recently that it has signed an exclusive option to enter a license agreement with Bessor Pharma, LLC a translational drug development company led by industry veteran Barry A. Berkowitz, Ph.D., for the development of ALB 109564(a), AMRI’s novel tubulin inhibitor compound in late Phase I testing for the treatment of cancer.
  8. ScinoPharm And National Health Research Institutes (NHRI) Announce Jointly Developed Diabetes Drug Approved For Phase I Clinical Trial 3/26/2012
    ScinoPharm (TWSE1789), a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, today announced its CRO project, DBPR108, commissioned by the National Health Research Institutes (NHRI), has received approval by Taiwan and the U.S. Food and Drug Administration (FDA) to commence a Phase I clinical trial.
  9. Harrison Clinical Research Selects BioClinica OnPoint CTMS 1/19/2012
    BioClinica, Inc., a global provider of clinical trial management solutions, announced recently a new agreement with Harrison Clinical Research (HCR), an international full-service contract research organization.
  10. Sumagen Initiates Clinical Testing Of Omnia Biologics Manufactured HIV Vaccine 1/12/2012
    Biologics drug development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that its customer Sumagen, Co., Ltd., (Seoul, S. Korea and London, ON) will begin clinical trials of their revolutionary HIV vaccine design.